Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 20 Issue 2, February 2002

An artificial antigen-presenting cell (APC) interacting with a cytotoxic T cell in vitro. June and colleagues have constructed APCs that express ligands for the T-cell receptor, CD28, and the 4–1BB costimulatory molecules (see p. 143). © Doug Struthers.

Editorial

Top of page ⤴

Business and Regulatory News

Top of page ⤴

Commentary

Top of page ⤴

Book Review

Top of page ⤴

Correspondence

Top of page ⤴

Feature

  • It took a leap of faith for researchers to believe that antisense technology might lead to novel medicines, but that commitment could soon pay off.

    • Alan Dove
    Feature
Top of page ⤴

News & Views

  • Engineered artificial antigen-presenting cells provide a defined system for the rapid expansion of cytotoxic T cells used in adoptive immunotherapy.

    • Mark E. Dudley
    News & Views
  • Combining data sets from phage display and yeast two-hybrid screens offers a more stringent approach for suggesting protein–protein associations.

    • Pierre Legrain
    News & Views
  • Completion of the Agrobacterium tumefaciens genome sequence opens new opportunities to engineer increased transformation efficiency and broader host range.

    • John Zupan
    • Doyle Ward
    • Patricia Zambryski
    News & Views
Top of page ⤴

News in Brief

Top of page ⤴

Review Article

Top of page ⤴

Article

Top of page ⤴

Technical Report

Top of page ⤴

Patents

Top of page ⤴

People

Top of page ⤴

New on the Market

Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Quick links